Objective: To assess maternal serum activin A, an early phase response protein in systemic infection, as an early marker of intrauterine infection in women with preterm prelabour rupture of membranes (PPROM).
Introduction
Optimizing the clinical management of women with preterm prelabour rupture of membranes (PPROM) remains a major obstetric challenge. PPROM precedes about one-third of all preterm births 1 and is further complicated by intrauterine infection (IUI; chorioamnionitis) in a third of cases. The development of chorioamnionitis is important because it increases the risk of cerebral palsy two-to fourfold. 2, 3 On the other hand, in the absence of infection, the fetus is best served by prolonging pregnancy, at least if PPROM occurs at less than 32 to 34 weeks' gestation [4] [5] [6] to afford the fetus the benefits of advanced maturity. Thus, current best practice would support expectant management in the absence of IUI and expedited delivery in the presence of infection. 7 Of course, to be successful, such a management strategy depends on the sensitive and timely detection of IUI. Herein lies the major problem because there are no early markers of IUI that have a sensitivity and specificity to be particularly clinically useful. Clinical symptoms such as maternal malaise, and signs such as abdominal tenderness, maternal pyrexia and tachycardia are usually apparent only late in the infective process and so are not useful in the prediction of infection. 8 Similarly, while in common use, neither the maternal white blood cell count (WCC) nor the level of C-reactive protein (CRP) are insightful as early markers of infection. 9, 10 Indeed, the WCC is transiently elevated by corticosteroids given to promote fetal lung maturity, 11, 12 potentially misleading clinicians to suspect infection. Even more direct assessments such as Gram stain and culture of amniotic fluid, collected by amniocentesis, or the measurement of inflammatory cytokines in amniotic fluid have not proven predictive. 10 Lastly, assessment of the fetus itself, whether by biophysical profile, cardiotocograph or Doppler ultrasound, has been shown to be uninformative regarding IUI. 13 Given the lack of a suitable early marker of infection, optimizing the care of women with PPROM is significantly hampered.
We believed that activin A, a member of the transforming growth factor-b superfamily, 14 might be a candidate marker of IUI. In pregnancy, activin A is secreted by the placenta and fetal membranes into the maternal circulation and amniotic fluid. [14] [15] [16] [17] Maternal serum levels of activin A are highest at term 18 and are increased in a variety of pregnancy complications including placental abruption, 19 preeclampsia [20] [21] [22] [23] and fetal growth restriction. 24, 25 In the context of infection, maternal serum levels of activin A are increased in association with preterm labor, particularly in those women who go on to give birth 26 and in vitro culture of amnion in the presence of proinflammatory mediators increases activin production. 27 More recently, it has become apparent that activin A may be an important player in the acute systemic inflammatory response. 28, 29 In particular, circulating levels of activin increase before other acute phase cytokines such as tumor necrosis factor (TNF)-a and the interleukins (ILs), 30 suggesting that activin A may be one of the first systemically detectable responses to infection in general. Accordingly, we undertook this study to explore whether maternal serum levels of activin A in women with PPROM may be a useful early warning of developing infection.
Methods

Patient selection and recruitment
We undertook a prospective cohort observational study approved by Southern Health Human Research Ethics Committee, between June 2007 and January 2008 at Monash Medical Centre. Women were eligible for inclusion if they had a singleton pregnancy complicated by confirmed PPROM at 24 to 34 weeks' gestation, defined by sterile speculum examination of pooling of liquor in the posterior vaginal fornix. 7 Women were excluded if there were clinical signs of infection at presentation (for example, maternal pyrexia X38 1C, tender uterus, offensive loss per vaginum, maternal/fetal tachycardia), if they were in active labor, had preeclampsia or a known placental abruption, or if the fetus was growth restricted. Informed written consent was obtained by a member of the research team at the time of initial presentation. On recruitment, an extra 5 ml blood sample was collected for subsequent analysis of activin A and other cytokines. Blood was also collected for activin and cytokine profiling whenever venepuncture was undertaken as part of routine clinical care. Clinical management of all women was as per hospital protocol, namely oral erythromycin for 10 days, two 11.4 mg doses of betamethasone (Celestone Chronodose), twice weekly venepuncture for a full blood examination and a CRP, and fetal surveillance (biophysical profile, amniotic fluid index, Doppler ultrasound, cardiotocograph) at the discretion of the clinical team. All women were reviewed on a daily basis to assess the presence or absence of IUI. Clinicians and patients were blinded to the activin A and cytokine results. Following birth, the placentae were sent for histological examination, specifically looking for chorioamnionitis or funisitis, as previously defined. 31 Women were defined to have chorioamnionitis on both clinical and histological criteria.
Assays
Total activin A was measured using a commercial enzyme-linked immunosorbent assay (DSL, Webster, TX, USA) with minor modifications as described previously. 32 Maternal serum was diluted 1:10 with assay diluent before assay. The sensitivity of the assay was 72 pg ml À1 and the mean intra-and interassay coefficients of variation were 8 and 15%, respectively. A multiplex assay (Bio-Plex; Bio-Rad Laboratories, Hercules, CA, USA) was used to simultaneously analyze 17 human pro-and antiinflammatory cytokines (IL-1, IL-2, IL-4, IL-5, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, MIP-1b, MCP-1, G-CSF, GM-CSF, IFN-g, MCP-1 and TNF-a). Maternal serum was diluted 1:2 with assay diluent before assay. The Bio-Plex assay is a dual-laser solution-array that utilizes a mixture of color-coded polystyrene beads each coated with specific antibody in a 96-well filter-plate. Bound analytes are identified using a cocktail of biotinylated secondary antibodies followed by streptavidin-PE. The flow-based system uses one laser to identify the bead signature (the analyte) whereas the second laser measures PE fluorescence intensity (the concentration). Bio-Plex Manager software (v4.1; Bio-Rad Laboratories) automatically plots each standard curve using a 5-parameter logistic regression curve fit and determines analyte concentration. For the Bio-Plex assay we chose to include all cases of chorioamnionitis and an equal number of randomly selected noninfected cases for comparison.
Statistical analyses
Analyses were performed using SPSS Version 14.0. Relationships between demographic characteristics and infection were explored using Student's t-test and the w 2 -test for independence. Due to the violation of the minimal expected cell frequency assumption, the Fisher Exact Probability test was used to interpret results. Comparisons between serum results and infection were done using Mann-Whitney U-test. Significance was accorded when Pp0.05.
Results
Eighteen women with PPROM participated in the study. Table 1 summarizes their demographic characteristics. Subsequent to recruitment, seven women developed IUI. Intravenous substance abuse was significantly more common in women who developed IUI. Otherwise there were no significant differences between the two groups of women.
A post hoc power calculation was performed. Assuming equal sample sizes, a 95% confidence level (alpha 0.05) with statistical power of 0.90 (beta 0.10) would require a sample size of six in each group to detect a twofold difference in group means (IUI vs no IUI) with a sigma of 0.5. Results are presented from venepuncture at admission and within 72 h of delivery. We believed such time points would afford the greatest clinical opportunity; admission results to triage care based on risk of infection and then results within 72 h of delivery to identify early infection and allow a change in management. Table 2 summarizes the serum concentration of activin A, WCC and CRP. There were no differences in serum activin A levels between women with infection and those without, either on admission or proximate to delivery (Figure 1) . Selected results of the multiplex assay from seven women with and without infection are shown in Table 3 . On admission, there were no differences in any of the analytes between women who developed IUI compared to those who did not.
Compared to women without infection, within 72 h of delivery, women with infection had a higher WCC (P ¼ 0.03), higher IL-6 (P ¼ 0.05) and IL-10 (P ¼ 0.009) levels and lower IL-7 levels (P ¼ 0.04 Tables 2 and 3 ). There were no differences in either CRP levels or in levels of any of the other cytokines (IL-1, IL-2, IL-4, IL-5, IL-8, IL-12, IL-13, IL-17, MIP-1b, MCP-1, G-CSF, GM-CSF, IFN-g, MCP-1 and TNF-a) between the two groups.
Discussion
Prompt rescue of the fetus at a time that safely maximizes fetal maturity while minimizing the risk of infection is the cornerstone of the modern management of PPROM. Ideally, predicting which women might develop infection at their initial presentation could allow for intensive surveillance and a lower delivery threshold. In this study, we addressed whether activin A might be a useful marker of infection in PPROM and have shown, unfortunately, that it is not.
IUI rates were relatively high in our study, with 7 out of 18 (39%) women developing chorioamnionitis. Disappointingly, there were no differences in activin A levels between infected and noninfected women either at admission or in the 72 h before delivery. Our rationale for assessing activin A in this setting was that activin A is released early in the acute systemic response. 29 In an experimental ovine model of infection, increased circulating activin A was apparent just 1 h after injection of lipopolysaccharide, significantly before increases in TNF-a and IL-6. 30 It was this immediate inflammatory response and an association with preterm labor that drew our attention to the possibility that activin may be an early marker of IUI. We were further encouraged that, unlike the peripheral WCC, 11, 12 activin A levels are unchanged by the administration of glucocorticoids. 33 Although our sample size was small, had circulating levels of activin A been altered by chorioamnionitis we would have expected to have observed this as we detected significant differences in other inflammatory markers (IL-6, IL-7 and IL-10) within 72 h of delivery. Accordingly, we conclude that activin is not a useful marker of infection in PPROM. Our observation that IL-6, IL-7 and IL-10 were different in women with infection proximate to delivery confirms a previous report, 34 but none of the markers were elevated on admission affording an opportunity to triage care early.
This study is limited by its small sample size to draw further conclusions, however, it was intended to investigate activin foremost, with the Bio-Plex assay positioned as a comparative tool. It may be of value in a larger study to assess a combination of markers to additionally differentiate between patients. Further, we chose a single serum sample taken within 72 h of delivery for analysis, and results may have been more discriminatory if all the samples were in the day before delivery. However, we felt that the 72-h window would be clinically useful in affording sufficient time to initiate a change in management, be it delivery or additional antibiotic therapy, before overt infection. Efforts to prolong pregnancy must be underpinned by sensitive markers of IUI, and perhaps targeted to fetal inflammatory responses, particularly given the pitfalls in clinical diagnosis. A noninvasive approach, although preferable, does not currently exist. Of note, amniocentesis is not employed routinely at our institution for PPROM, and we are therefore unable to compare activin with other markers in the amniotic fluid. Indeed, amniocentesis may offer detection of subclinical infection by positive amniotic fluid cultures and cytokine profiling and allow tailoring of specific antibiotic therapy; however, it remains to be determined whether its use improves neonatal outcomes. 7 As such, thorough clinical assessment, despite its limitations, rather than routine pathology or invasive testing, would appear to remain the mainstay of management of women with PPROM.
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